POOLBEG PHARMA LS -0002
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more
POOLBEG PHARMA LS -0002 (7JN) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, POOLBEG PHARMA LS -0002 (7JN) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
POOLBEG PHARMA LS -0002 - Net Assets Trend (None–None)
This chart illustrates how POOLBEG PHARMA LS -0002's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for POOLBEG PHARMA LS -0002 (None–None)
The table below shows the annual net assets of POOLBEG PHARMA LS -0002 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to POOLBEG PHARMA LS -0002's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
POOLBEG PHARMA LS -0002 Competitors by Market Cap
The table below lists competitors of POOLBEG PHARMA LS -0002 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hizeaero Co. Ltd
KQ:221840
|
$20.27 Million |
|
Visi Media Asia Tbk
JK:VIVA
|
$20.28 Million |
|
Information and Communication Networks Public Company Limited
BK:ICN
|
$20.30 Million |
|
Smartiks Yazilim AS
IS:SMART
|
$20.31 Million |
|
Mirae Asset SPAC 4
KQ:222420
|
$20.26 Million |
|
Jourdeness Group Ltd
TW:4190
|
$20.26 Million |
|
Pampa Metals Corporation
OTCQB:PMMCF
|
$20.26 Million |
|
PARADISE ENTERT. HD -001
F:LIL3
|
$20.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in POOLBEG PHARMA LS -0002's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares POOLBEG PHARMA LS -0002's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently POOLBEG PHARMA LS -0002 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares POOLBEG PHARMA LS -0002's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| POOLBEG PHARMA LS -0002 (7JN) | €- | N/A | N/A | $20.27 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |